Introduction {#S1}
============

Bipolar disorder (BD) is a severe psychiatric disorder characterized by episodes of extremely elevated, expansive or irritable mood, grandiosity, flight of ideas, distractibility or agitation. These symptoms lead often to marked impairment in social and occupational functioning.^[@R1]^ Episodes of mania are frequently followed by severe and disabling depression. In general, BD is conceptualized as a complex disease with genetic and environmental risk factors.^[@R2]^ Heritability estimates range from 58% to 93% with monozygotic twin concordance of about .43.^[@R3],[@R4]^ Nevertheless, the etiology of the disease remains unknown. Linkage studies and genome-wide association studies (GWAS) have suggested chromosomal and genomic regions potentially related to BD, but the identification of disease causing variants remains largely elusive.^[@R5],[@R6]^ Exome-wide sequencing offers now a new opportunity to lead these investigations to a new level.

BD is a common psychiatric disorder with a population prevalence of 2--3%.^[@R7],[@R8]^ However, families in which the disorder is transmitted over several generations are very rare. In the hope of finding genetic risk factors for BD with strong effect, the National Institute of Mental Health (NIMH) ascertained a number of these families in which a Mendelian mode of transmission was suggested by the pattern of disease segregation.^[@R9]^ However, after initial enthusiasm it was quickly realized that a single genetic risk factor with strong effect would most likely not explain the susceptibility to BD even in severely affected multigenerational families.^[@R10]--[@R12]^ Instead, mathematical model fitting suggested an oligogenic risk profile as the most likely cause of the disease, but indicated also substantial interfamilial heterogeneity.^[@R13]^ Early linkage studies were not equipped to perform well under this scenario and knowledge about the human genome was still in its infancy.

Since these early attempts had been unsuccessful in finding rare disease causing genes in BD, the search for common genomic polymorphisms as disease modifiers of BD dominated the literature. Many reviews on this subject have been published and it is beyond the scope of this paper to cover this extensive literature. Instead, it is the intend of this paper to collect and present supporting evidence for the hypothesis that rare mutations might contribute to the risk of developing BD under an oligo genic mode of inheritance.

With human genome data available and falling sequencing costs, the time seems right to revisit the original models of disease transmission in the families of the NIMH BD genetics initiative. We conducted a family-based exome sequencing study in multigenerational families of the NIMH to test the hypothesis that several rare functional mutations in gene coding regions are co-transmitted over several generations and shared identity by descent among the affected family members. We expected that the mutated genes would cluster into functional pathways suggesting potential disease path mechanisms. Large, population based samples of patients with schizophrenia and healthy controls were also available to test disease association and disease specificity.

Methods {#S2}
=======

Sample selection {#S3}
----------------

The analysis presented in this article was based on publicly available data and biomaterial from families of the NIMH Bipolar Genetics Initiative.^[@R14]^ We selected nine affected individuals from four Caucasian families in which BD was transmitted over several generations following an apparently Mendelian mode of inheritance. In three families, we selected the two most distantly related affected family members for exome-wide sequencing. In one family, we selected three affected individuals, since the disease appeared to be transmitted through the paternal and the maternal lineage. The ethnicity of the individuals was determined based on self-report. All affected and unaffected family members, and also the independent patients had been interviewed with the Diagnostic Interview for Genetic Studies (DIGS) by trained health care professionals blinded to the clinical diagnosis. The DIGS is an extensively validated, structured clinical instrument developed by principal investigators at the NIMH for the assessment and differential diagnosis of major mood and psychotic disorders. Medical and psychiatric comorbidities were also recorded.^[@R15]^ Non-hierarchical Best Estimate consensus diagnoses were reached by at least three independent raters according to DSM-IV criteria.^[@R16],[@R17]^ In addition, we randomly selected six unrelated individuals with BD for exome-wide sequencing, who had been evaluated under the same procedures.

Exome sequencing and bioinformatics analysis {#S4}
--------------------------------------------

DNA was isolated from immortalized lymphoblastoid cell lines. Genomic DNA extraction, library preparation, sequencing, and data analysis were performed using established procedures. Exome capture was carried out using the Illumina TruSeqTM Exome Enrichment Kit (Illumina Inc., San Diego, CA) and the DNA was sequenced using the HiSeq 2000 for a 100-bp paired-end run (Illumina Inc., San Diego, CA). An average of 50 million independent paired reads were generated per sample to provide a mean 10-fold coverage across the RefSeq protein-coding exons and flanking intronic sequence (±2 bp) of more than 87.5% of these bases and a mean 20-fold coverage of 78.9% of the targeted sequences ([Supplementary Information](#SD1){ref-type="supplementary-material"}). As technical controls during the sequencing process and to guard against technical artifacts, we used the DNA of 200 unrelated individuals who were sequenced in our laboratory under the same exon capture and sequencing conditions.

Variant annotation, filtering and interpretation {#S5}
------------------------------------------------

Single nucleotide variants (SNV) and small structural variants including insertions and deletions were annotated using Golden Helix SNP & Variation Suite (SVS) v8.1.^[@R19]^ Variants were filtered based on evidence for identity by descent sharing among affected family members, minor allele frequency (MAF) \<= 0.01%, and predictions regarding consequence on protein function by the following in silico prediction tools: SIFT, PolyPhen 2, LRT, MutationTaster, Mutation Assessor, and FATHMM ^[@R20]--[@R26]^ ([Figure 1](#F1){ref-type="fig"}). The filtered variants were then genotyped in additional affected family members. In addition, all selected variants were also genotyped in at least one unaffected family member per family. Based on these results, we selected variants that were present in the affected family members and absent in the unaffected family members. Finally, we used the exome data from the Sweden-Schizophrenia (SZ) Population-Based Case-Control Exome Sequencing dataset (dbGAP accession: phs000473.v1.p1) for a case control association analysis on the selected variants. This dataset contained exomic data of 2 545 individuals with SZ and 2 545 controls.

Statistical analysis {#S6}
--------------------

To determine the statistical significance of mutation-frequency differences between cases and controls, we used the Fisher's exact test for rare variants^[@R27]^ and corrected for multiple testing using the Bonferroni procedure.^[@R28]^ In this analysis, the family was considered to be the unit of observation since only variants shared among the affected family members were included in the analysis. Pathway analysis and gene set enrichment analysis (GSEA) of variants that were significant in the Fisher's exact test were performed in DAVID (DAVID Bioinformatics Resource 6.7).^[@R29]--[@R32]^

Results {#S7}
=======

Sample characteristics {#S8}
----------------------

In four multigenerational families, multiple individuals were affected with a severe and complex type of BD ([Table 1](#T1){ref-type="table"}). The patients had been diagnosed with BD on average at 18 years of age (*SD*=7.7), and at the time of interview, the majority of the patients had been ill for at least 15 years. Only one fifth of the patients were male (20%). Almost all selected patients (93%) had been diagnosed with bipolar disorder type 1 (BD1) according to DSM-IV criteria, but one independent patient carried the diagnosis of bipolar disorder type 2 (BD 2). Eight patients (53%) fulfilled criteria for rapid cycling BD, a disease subtype characterized by at least four separate mood episodes over the course of one year. Ten patients (67%) had experienced symptoms of hallucinations and/or delusions and ten patients (67%) had attempted suicide at least once during the disease course. All patients had been diagnosed with one or more psychiatric comorbidities, including anxiety disorders (73%), substance use disorders (SUDs) (60%), attention-deficit hyperactivity disorder (40%), obsessive compulsive disorder (OCD) (27%), sleep disorders (27%), eating disorders (20%), and antisocial personality disorder (20%). In addition, some patients also had medical disorders that could have contributed to the phenotype variability. Among these disorders were migraine (67%), seizure disorders (33%), thyroid disorders (20%), gastrointestinal disorders (20%), metabolic disorders (13%), and cardiovascular disorders (7%). Almost half of the sample had been diagnosed with learning disability (40%).

Identification of rare, damaging, and disease-specific mutations {#S9}
----------------------------------------------------------------

Whole-exome sequencing and genotyping of the 15 affected individuals identified 14 rare and likely damaging mutations that were shared identity-by-descent. The mutations were absent in the unaffected family members and also in the technical controls ([Figure 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). Seven of these mutations were novel and seven variants had been described previously in un-phenotyped population samples at very low frequency ([Table 3](#T3){ref-type="table"}). The variants were of high quality and predicted to be damaging for the protein structure or function by at least three functional predictors ([Supplementary Information Table S1 and S2](#SD1){ref-type="supplementary-material"}). In addition, we found one novel frameshift mutation and one known, rare deletion/insertion mutation, both with unknown functional consequences ([Table 3](#T3){ref-type="table"}). The mutations were private to the individual families, in which they were discovered, and none of the mutations were present in 2 545 ethnically matched controls (P≤1.6×10^−3^). Furthermore, none of the 2 545 exomes of patients with SZ carried the same mutations, indicating disease-specificity. Three of the mutated genes, *myosin IXA (MYO9A)*, *TBC1 domain family, member 10C* (*TBC1D10C)*, and *Rho GTPase activating protein 32* (*ARHGAP32)* had GTPase-activating function, but *in silico* analysis in DAVID revealed no statistically significant clustering of the mutated genes in any known pathophysiological pathway.

In addition to these 15 variants, we discovered two known, rare, compound heterozygous variants in the gene *solute carrier family 22 (organic cation transporter), member 1* (*SLC22A1)* in one severely affected individual. The first mutation (rs55918055) was inherited through the paternal lineage and the second mutation (rs34059508) was inherited through the maternal lineage. These non-synonymous coding mutations were predicted to be deleterious. We also identified mutations in known, disease-causing genes for several medical conditions that could have had disease modifying effects ([Supplementary Information Tables S3 to S6](#SD1){ref-type="supplementary-material"}). For example, a patient with seizure disorder carried a mutation in the gene *prickle homolog 1 (Drosophila)*\] (*PRICKLE1)*, a known gene for progressive myoclonic epilepsy 1B (EPM1B, MIM:612437). In one family, a novel mutation in the gene *dispatched homolog 1 (Drosophila)* (*DISP1)* segregated with the disease phenotype. Mutations in *DISP1* are known to cause holoprosencephaly (HPE) type 2--4 (HPE2, MIM:157170; HPE3, MIM:142945; HPE4, MIM:142946; HPE5, MIM:609637), and in addition, this gene is also known as the main suspect in the Chromosome 1q41--q42 deletion syndrome (MIM:612530). Since epilepsy and holoprosencephaly could present with seizures, mood symptoms, psychosis, developmental delay, and learning disabilities, mutations in these two genes could explain some of the neuropsychiatric phenotypes that segregated in two of the families. The gene Ankyrin Repeat and Kinase Domain Containing 1 (*ANKK1)*, which has been related to migraine and alcohol dependence,^[@R33]--[@R35]^ also carried a likely damaging mutation. The gene *T-box 2 (TBX2)* has been related to cognitive and behavioral abnormalities in the chromosome 17q23.1-q23.2 deletion syndrome (MIM:613355)*,* and *toll-like receptor 5* (*TLR5)* has been associated with systemic lupus erythematosus (SLEB1*,* MIM:601744). None of the variants could be replicated in the independent patients with BD.

Discussion {#S10}
==========

We identified rare, deleterious, and likely disease-causing mutations in gene-coding regions through unbiased, exome-wide sequencing in families with bipolar disorder (BD). Each family carried rare mutations in several genes that were shared identity-by-descent by affected family members and the variants were absent in the unaffected family members. All variants were predicted to be damaging by several in silico functional predictors. In each several rare, damaging mutations were associated with the disease. These findings are consistent with the currently favored hypothesis of oligo genic disease-causation in BD.^[@R36],[@R37]^

Exome-sequencing is increasingly utilized to identify very rare and likely disease causing mutations in many neuropsychiatric disorders.^[@R38]^ Our focus on rare and even private mutations is consistent with current trends in genetic epidemiologic research; however, our study is one of the first to examine the exomes of BD patients from multigenerational families in an unbiased, genome-wide approach, and to evaluate the results in the context of a large number of population-based healthy controls and patients with SZ. The results of this study reveal a complex scenario of rare and private missense and loss-of-function mutations in novel candidate genes. In addition, we found mutations in known disease-causing genes for medical conditions that could have potentially had disease modifying effects, for example on intellectual ability or immune status.

Our results could be viewed in the context of previously published linkage analyses in the families of the NIMH genetics initiative. Genome-wide significant linkage signals have been reported in the chromosomal regions 16p12.2 and 17q12^[@R39],\ [@R40]^ (Dick et al, 2003; Chen et al., 2006). The region 16p12.2 has also been linked to the sub-phenotype psychosis and suggestive linkage has been found to the chromosomal regions 19p13 with the same phenotype^[@R40]^ (Chen et al., 2006). However, when considering linkage results it has to be kept in mind that linkage regions on average contain hundreds of genes, and therefore, conclusions about supporting evidence of linkage results should be viewed with great caution.

Our conclusion about a causal relationship between the described variants and BD is plausible and coherent with some pathophysiological theories. Especially GTPase-activation is a pathophysiological process that is supported by animal models and cell culture experiments.^[@R41]--[@R43]^ GTPases are a target of lithium, a drug frequently used to treat BD; and therefore, a role for G-proteins in disease processes of BD has long been hypothesized.^[@R44]--[@R59]^

The patients with BD had also been diagnosed with a number of medical and neurological disorders including seizure disorders and learning disability. Therefore, it is highly likely that some of the identified genes might in fact be related to these disorders rather than to BD itself. In fact, we were able to identify rare mutations in genes that have previously been linked to seizure disorders and holoprosencephaly. These conditions could potentially modify the disease expression and the disease course of BD. Since none of the protein-damaging mutations were present in patients with SZ, shared genetic risk factors between BD and SZ might be uncommon.

Limitations of our study are (1) the very small sample size of BD patients in this data set. This limitation could result in an underestimation or overestimation of the effect size of these rare and private mutations. Given the rare nature of the variants in the general population, replication of individual variants is highly unlikely. Another limitation of our analysis was the dependence on *in silico* functional predictions. Many examples indicate that these predictions might not always reflect the true biological, cell-specific consequences of a specific mutation on an individual's genetic background. Therefore, it is recommended to test the functional consequences of the identified mutations and experimentally validate the effect in cell culture assays and in *in vivo* models. Despite obvious limitations, our results are consistent with previous publications in the literature. For example, several groups have identified rare functional mutations in BD families,^[@R60]--[@R62]^ even though statistical significance after correction for multiple testing in larger samples still needs to be established. In addition, rare structural variants have been associated with BD, but the functional consequences of these variants remain to be determined.^[@R63],[@R64]^

While individual mutations and genes still require further support before generalizable conclusion can be drawn, it has become clear that BD is by far more heterogeneous than previously anticipated. Our results support a rare-variant oligo genic disease models in families with BD and stress the importance of protein-coding regions. Based on these results, we recommend to fund studies that focus on multi-generational families to identify functional mutations. Furthermore, in clinical practice, it should be recognized that in some families, BD might be transmitted with higher risk than generally anticipated in the framework of common, complex disorder, and that genetic counseling might be recommended. Exome-wide sequencing could be useful in high-risk families to identify known disease-causing mutations for neuropsychiatric disorders that might resemble BD, such as holoprosencephaly and seizure disorders.

Conclusions {#S11}
===========

The results of our study indicate that rare, deleterious mutations in gene-coding regions could be related to a BD phenotype in families, in which the disease is transmitted over several generations. Exome sequencing in multigenerational families with BD is effective in identifying rare genomic variants with potential clinical relevance. Our results further support the rare-variant oligo genic disease model of BD. The disease association of the identified mutations need to be replicated and the functional consequences of the mutations validated before the information could be used in clinical settings.
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![Selection algorithm for rare variants in families with bipolar disorder\
The figure delineates the algorithm that was used to select potentially disease-causing mutations in four families with bipolar disorder. SZ, schizophrenia.](nihms807677f1){#F1}

###### 

Phenotype of affected individuals in four families with bipolar disorder

                                                 N=15, %
  ---------------------------------------------- -------------
  Age, years (SD)                                38.4 (15.6)
  Age of onset of bipolar disorder, years (SD)   18.2 (7.7)
  Gender, male                                   3 (20)
  Diagnosis of bipolar disorder type 1,          14 (93)
  Rapid cycling                                  8 (53)
  Suicide attempts                               10 (67)
  Psychosis                                      10 (67)
  **Psychiatric comorbidity**                    
  Anxiety disorder                               11 (73)
  Attention deficit hyperactivity disorder       6 (40)
  Substance use disorder                         9 (60)
  Obsessive compulsive disorder                  4 (27)
  Antisocial personality disorder                3 (20)
  **Medical comorbidity**                        
  Seizure disorder                               5 (33)
  Migraine                                       10 (67)
  Disorders of the endocrine system              3 (20)
  Disorders of the metabolic system              2 (13)
  Disorders of the cardiovascular system         1 (7)
  Disorders of the gastrointestinal system       3 (20)
  Learning disability                            6 (40)
  Sleep disorder                                 4 (27)
  Eating disorder                                3 (20)

###### 

List of mutated genes in bipolar disorder families

  Entrez \#   Gene       Name                                                                        Function
  ----------- ---------- --------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  9743        ARHGAP32   Rho GTPase activating protein 32                                            GTPase activator activity (GO:0005096), phosphatidylinositol binding (GO:0035091)
  60314       C12orf10   chromosome 12 open reading frame 10                                         locomotory exploration behavior (GO:0035641)
  84516       DCTN5      dynactin 5 (p25)                                                            Centrosome (GO:0005813)
  2060        EPS15      epidermal growth factor receptor pathway substrate 15                       calcium ion binding (GO:0005509) protein binding (GO:0005515)
  2568        GABRP      Gamma-Aminobutyric Acid (GABA) A Receptor, Pi                               GABA-A receptor activity (GO:0004890)
  115399      LRRC56     leucine rich repeat containing 56                                           unknown
  4649        MYO9A      myosin IXA                                                                  regulation of small GTPase mediated signal transduction (GO:0051056)
  84700       MYO18B     myosin XVIIIB                                                               vasculogenesis (GO:0001570)
  284434      NWD1       NACHT and WD repeat domain containing 1                                     ATP binding (GO:0005524)
  5286        PIK3C2A    phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha   1-phosphatidylinositol-3-kinase activity (GO:0016303)
  4660        PPP1R12B   Protein Phosphatase 1, Regulatory Subunit 12B                               small GTPase mediated signal transduction (GO:0007264)
  5829        PXN        Paxillin                                                                    activation of MAPK activity (GO:0000187)
  374403      TBC1D10C   TBC1 domain family, member 10C                                              regulation of Rab GTPase activity (GO:0032313)
  7158        TP53BP1    tumor protein p53 binding protein 1                                         RNA polymerase II activating transcription factor binding (GO:0001102)
  143630      UBQLNL     ubiquilin-like                                                              protein binding (GO:0005515)
  146862      UNC45B     Unc-45 Homolog B (C. Elegans)                                               chaperone-mediated protein folding (GO:0061077)

###### 

Molecular characteristics of mutations in families with bipolar disorder

  Location       Chromosome   Gene       Identifier    Transcript     Exon   Coding                 Protein
  -------------- ------------ ---------- ------------- -------------- ------ ---------------------- --------------------
  11:128838929   11q24.3      ARHGAP32   novel         NM_014715      13     c.5090G\>T             p.Gly1697Val
  12:53694010    12q13.13     C12orf10   novel         NM_021640      2      c.293A\>G              p.Tyr98Cys
  16:23672532    16p12.2      DCTN5      novel         NM_001199743   4      c.278T\>C              p.Ile93Thr
  1:51826856     1p32.3       EPS15      rs148821171   NM_001159969   12     c.1589C\>T             p.Ala530Val
  5:170238979    5q35.1       GABRP      novel         NM_014211      10     c.1040A\>T             p.Glu347Val
  11:549982      11p15.5      LRRC56     novel         NM_198075      7      c.407_408insT          p.Ser136fs
  15:72191038    15q23        MYO9A      novel         NM_006901      25     c.3806G\>A             p.Arg1269Gln
  22:26224877    22q12.1      MYO18B     rs373113816   NM_032608      15     c.2921G\>A             p.Arg974His
  19:16860396    19p13.11     NWD1       rs148848880   NM_001007525   6      c.943C\>T              p.Arg315Cys
  11:17172051    11p15.1      PIK3C2A    novel         NM_002645      3      c.1321T\>G             p.Cys441Gly
  1:202398004    1q32.1       PPP1R12B   rs199816573   NM_001167857   6      c.868G\>A              p.Ala290Thr
  12:120650260   12q24        PXN        novel         NM_025157      11     c.1132C\>T             p.Arg378Cys
  11:67172591    11q13.2      TBC1D10C   rs201081455   NM_198517      3      c.188G\>A              p.Arg63Gln
  15:43762077    15q15.3      TP53BP1    rs28903074    NM_001141979   11     c.1362_1367delTATCCC   p.454_456delinsPro
  11:5537397     11p15.4      UBQLNL     rs7933557     NM_145053      1      c.275A\>T              p.Asp92Val
  17:33504148    17q12        UNC45B     rs137917897   NM_001033576   16     c.2138G\>A             p.Arg713Gln
